TREMELIMUMAB + Olaparib for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Oct 2015: Trial registered, NCT02571725
  2. 23 Feb 2016: Trial started, NCT02571725

The trials

NCT02571725: PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

State
Under way
Phase
Phase 1 and Phase 2
People
50 planned
Started
23 Feb 2016
Primary completion
2 Dec 2020
Arms
Olaparib and Tremelimumab
Results
None posted
  1. 8 Oct 2015: Trial registered
  2. 23 Feb 2016: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.